Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release
Milon de Jong, Myrthe Veth, Tereza Brachtlová, Lisa A King, José Saura-Esteller, Tamara M Bechler, Pauline M van Helden, Canan Alhan, Roeland Lameris, Tanja D de Gruijl, Hans J van der Vliet · 2026
Read Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release by Milon de Jong, Myrthe Veth, Tereza Brachtlová, Lisa A King, José Saura-Esteller, Tamara M Bechler, Pauline M van Helden, Canan Alhan, Roeland Lameris, Tanja D de Gruijl, Hans J van der Vliet (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13331140.txt.
Description
Milon de Jong and colleagues test whether lenalidomide boosts a dual-target antibody that recruits a special T cell type in a 2026 study. The target cells kill tumours without the usual matching limits. Standard drugs for myeloma and marrow disorders were screened for help or harm beside the antibody in lab tests.
Lenalidomide stood out with synergy, lifting T cell activation, granule release, and growth factor output in the reported assays. Paths involved stronger CD28 signalling, Notch activation, and interleukin-2 release. In marrow samples from syndrome patients, the drug enabled T cell growth that the antibody alone failed to spark. A combined clinical test is justified, the authors argue.
Catalog record
| CREATOR | Milon de Jong, Myrthe Veth, Tereza Brachtlová, Lisa A King, José Saura-Esteller, Tamara M Bechler, Pauline M van Helden, Canan Alhan, Roeland Lameris, Tanja D de Gruijl, Hans J van der Vliet |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53482 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |